Fig. 4.

shRNA-mediated knockdown of AURKA reduces xenograft tumor growth. a A549 stable cells with inducible expression of a shRNA targeting AURKA (shAKA) or a non-targeting shRNA (shCtrl) were injected subcutaneously in nude mice (n = 9 per group). shRNA expression was induced by doxycycline (DOX) administration in the drinking water as described in methods (n = 5 per group). Alternatively, mice were left untreated (MOCK) to control for doxycycline-mediated effects (n = 4 per group). The graph shows tumor volume measurements, which were initiated 26 days after inoculation (day 0). Error bars represent average ± 1 s.d. b Representative images of the tumors at day 56 after inoculation. c A549 stable cells with inducible expression of a shRNA targeting AURKA (shAKA) or a non-targeting shRNA (shCtrl) were injected subcutaneously in nude mice (n = 12 per group). shRNA expression was induced by doxycycline (DOX) administration in the drinking water as described in methods (n = 6 per group). Tumor weights at day 56. Error bars represent average ± 1 s.d. In all cases, statistical significance was determined when appropriate by one-way analysis of variance (ANOVA) followed by Bonferroni’s multiple comparison test (a) or by Student's t-test (c) (*p < 0.05) and the significantly different comparisons are indicated by vertical (a) or horizontal (c) bars. d Protein lysates of xenograft tumors were submitted to western blotting with the indicated antibodies. ACTB) anti-β-actin